Tirzepatide versus semaglutide In the direct head-to-head comparison, the 1-year risk of the primary endpoint including all-cause mortality was 1.3% (95% CI 1.2% to 1.5%) for tirzepatide and 1.3% (95% CI 1.2% to 1.5%) for semaglutide, resulting in a risk difference of 0.0% (95% CI 0.2% to 0.2%) and an HR of 1.06 (95% CI 0.95 to 1.18) (Fig
Nu bn ang quan tm n cc sn phm ca Cocolux, hy ghe qua Cocolux hoc website cocolux.com c t vn va mua hang vi mc gia hp dn, nhiu u ai
Pancreatitis during treatment with liraglutide
Methods Inclusion Criteria Patients aged 65 years or older visiting the geriatric outpatient clinic or admitted to the geriatric ward at Spaarne Gasthuis, Haarlem and Hoofddorp, Netherlands
Which therapies or use cases are best suited for expanded access (acute vs
The fierce competition is understandable: The GLP-1 market is expected to reach $100 billion by 2030